Kemp Dolliver
Stock Analyst at Brookline Capital
(0)
# 5017
Out of 5,329 analysts
24
Total ratings
16.67%
Success rate
-34.61%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
YMAB Y-mAbs Therapeutics | Initiates Coverage On: Buy | 17 | 4.1 | 314.63% | 1 | Dec 5, 2024 | |
EYEN Eyenovia | Downgrades: Hold | n/a | n/a | n/a | 2 | Nov 15, 2024 | |
VRCA Verrica Pharmaceutic... | Downgrades: Hold | n/a | n/a | n/a | 2 | Oct 2, 2024 | |
ONCT Oncternal Therapeuti... | Downgrades: Hold | n/a | n/a | n/a | 3 | Sep 12, 2024 | |
IBIO iBio | Initiates Coverage On: Buy | 4 | 1.02 | 252.94% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 36 | 2.96 | 1116.22% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 32 | 1.58 | 1887.34% | 1 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 27 13 | n/a | n/a | 1 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 100 | 106.09 | -5.74% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 57 | 2.38 | 2294.96% | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 5 | n/a | n/a | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 25 | 2.42 | 933.06% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 19 | 7.46 | 151.34% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 8 | 0.99 | 708.08% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 6 | 1.16 | 387.07% | 1 | Feb 2, 2022 |